Louisiana Bill: SB 253

Bill Summary

Louisiana SB253, effective August 1, 2026, prohibits professional and occupational licensing boards from preventing qualified healthcare providers from prescribing and providing peptides to patients. The bill requires that peptides be sourced from FDA-registered 503B outsourcing facilities or 503A compounding pharmacies that comply with federal regulations and USP-NF standards. It also protects Louisiana-licensed pharmacists working in out-of-state pharmacies from board prohibition when compounding and dispensing peptides under the same federal and quality standards. The prescribing provider bears responsibility for ensuring peptides meet all regulatory and quality requirements. This legislation removes regulatory barriers that previously limited patient access to peptide-based treatments.

Why It Matters to MAHA

MAHA strongly supports this bill because it expands patient autonomy and treatment options by removing unnecessary regulatory barriers that restrict healthcare providers from offering peptide therapies. The legislation protects health freedom by preventing licensing boards from blocking providers who are already authorized to prescribe medications from offering peptides, allowing patients greater choice in accessing innovative treatments. The bill maintains safety standards through FDA registration requirements and USP-NF compliance while eliminating bureaucratic obstacles that do not serve patient protection. By enabling Louisiana pharmacists and providers to work across state lines, SB253 increases access to treatments that patients and doctors believe are beneficial. This represents exactly the type of deregulation that MAHA advocates for: maintaining safety while expanding choice.